As shown in Fig. 6B, MTT assays demonstrated that HMGB3 overexpression promotes ovarian cancer cell proliferation, while AZD6244 or PD0325901 administration abrogates this effect. This evidence concerns the gene HMGB3 and ovarian carcinoma.